EcoDrugPlus

Trace Amine-Associated Receptor 1-Like

Ensembl ID : ENSOTSG00005007825
Gene Symbol: LOC112251703
3 Cross references
143 Possible Orthologues:

Transforming Growth Factor, Beta Receptor 1 A

Ensembl ID : ENSOTSG00005042389
Gene Symbol: TGFBR1A
1 Cross references
150 Possible Orthologues:

Transforming Growth Factor, Beta Receptor 1 B

Ensembl ID : ENSOTSG00005038648
Gene Symbol: TGFBR1B
1 Cross references
199 Possible Orthologues:

Transient Receptor Potential Cation Channel Subfamily A Member 1-Like

Ensembl ID : ENSOTSG00005020685
Gene Symbol: LOC112226907
3 Cross references
149 Possible Orthologues:

Transient Receptor Potential Cation Channel, Subfamily A, Member 1a

Ensembl ID : ENSOTSG00005029654
Gene Symbol: TRPA1A
1 Cross references
149 Possible Orthologues:

Transthyretin

Ensembl ID : ENSOTSG00005011725
Gene Symbol: TTR
3 Cross references
178 Possible Orthologues:

Tryptophan Hydroxylase 1

Ensembl ID : ENSOTSG00005004128
Gene Symbol: TPH1
3 Cross references
194 Possible Orthologues:

Tryptophan Hydroxylase 1 (Tryptophan 5-Monooxygenase) A

Ensembl ID : ENSOTSG00005021830
Gene Symbol: TPH1A
1 Cross references
158 Possible Orthologues:

Tryptophan Hydroxylase 1 (Tryptophan 5-Monooxygenase) A

Ensembl ID : ENSOTSG00005017531
Gene Symbol: TPH1A
1 Cross references
194 Possible Orthologues:

Tubulin Alpha Chain-Like

Ensembl ID : ENSOTSG00005022426
Gene Symbol: LOC112239137
3 Cross references
195 Possible Orthologues:

Tubulin Beta 3 Class Iii

Ensembl ID : ENSOTSG00005017643
Gene Symbol: TUBB3
1 Cross references
137 Possible Orthologues:

Tubulin Beta 3 Class Iii

Ensembl ID : ENSOTSG00005019285
Gene Symbol: TUBB3
1 Cross references
138 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).